

WEST Search History

DATE: Monday, April 26, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L23	5540912.pn.	2
<input type="checkbox"/>	L22	butuc.inv.	9
<input type="checkbox"/>	L21	5587149.pn.	2
<input type="checkbox"/>	L20	5668170.pn.	2
<input type="checkbox"/>	L19	4376118.pn.	2
<input type="checkbox"/>	L18	=1999	158
<input type="checkbox"/>	L17	L16 and polymer	1108
<input type="checkbox"/>	L16	L15 and solvent	1143
<input type="checkbox"/>	L15	L14 and viscosity	1234
<input type="checkbox"/>	L14	biocompatible and viscous and vehicle	1666
<input type="checkbox"/>	L13	biocompatible viscous vehicle	2
<input type="checkbox"/>	L12	L11 and l8	10
<input type="checkbox"/>	L11	L9 and viscous	8524
<input type="checkbox"/>	L10	L9 and viscous	5
<input type="checkbox"/>	L9	non-aqueous	71293
<input type="checkbox"/>	L8	L7 and l5	215
<input type="checkbox"/>	L7	L6.clm.	6985
<input type="checkbox"/>	L6	solvent adj20 polymer	87489
<input type="checkbox"/>	L5	L4 and l3	6547
<input type="checkbox"/>	L4	(424/\$).ccls. or (514/\$).ccls.	225291
<input type="checkbox"/>	L3	=1999	117361
<input type="checkbox"/>	L2	l1 and viscos\$3	165898
<input type="checkbox"/>	L1	solvent and polymer	464364

END OF SEARCH HISTORY

09497422blessing

> d his

(FILE 'HOME' ENTERED AT 18:34:22 ON 26 APR 2004)

FILE 'CAPLUS, USPATFULL' ENTERED AT 18:34:36 ON 26 APR 2004

L1	352350	S	SURFACTANT
L2	1775006	S	POLYMER
L3	1294051	S	SOLVENT
L4	78803	S	L1 AND L2 AND L3
L5	10758	S	L1 (P) L2 (P) L3
L6	1130152	S	NON-AQUEOUS OR WITHOUT WATER OR WITH OUT WATER OR NO WATER
L7	5112	S	L6 (P) L5
L8	194848	S	VISCOUS?
L9	67	S	L7 (P) L8
L10	105796	S	?VINYLPIRROLIDONE OR ?VINYL PYRROLIDONE
L11	716	S	LAURYL LACTATE
L12	17641	S	POLYSORBATE OR POLY SORBATE
L13	75	S	L10 AND L11 AND L12
L14	75	S	L13 AND L6
L15	0	S	L10 (P) L11 (P) L12
L16	2	S	L10 (P) L11
L17	2474	S	L10 (P) L12
L18	12	S	L11 (P) L12
L19	12	S	L18 AND L6
L20	3	S	L18 (P) L6

blessing

L20 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:12612 USPATFULL
 TITLE: Compositions for treating keratinous surfaces
 INVENTOR(S): Detore, Donna Marie, Morris Plains, NJ, UNITED STATES
 Reinhart, Gale McElroy, Middletown, NJ, UNITED STATES
 Ferone, James Joseph, Bridgewater, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009130	A1	20040115
APPLICATION INFO.:	US 2002-190804	A1	20020708 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Revlon Consumer Products Corporation, 625 Madison Avenue, New York, NY, 10022		
NUMBER OF CLAIMS:	42		
EXEMPLARY CLAIM:	1		
LINE COUNT:	928		
AB	A cosmetic composition comprising a mixture of extracts from yam and soy in combination with at least one protective agent which is a daytime protective agent, a night time protective agent, or mixtures thereof and methods for ameliorating the adverse effects of aging and menopause on skin.		
DETD	[0129] An oil-in-water emulsion cream suitable for day time wear was prepared as follows:		

INGREDIENT	w/w %
Butylene glycol	5.0
Preservatives	1.73
Magnesium Ascorbyl Phosphate	0.01
Silica. . . 2.0	
Cetyl Alcohol	1.5
Stearyl Alcohol	0.75
Talc	0.75
PPG-2 Myristyl Ether Propionate	4.5
C12-15 Alkyl Benzoate	1.0
Tocopheryl Acetate	0.1
Aloe Barbadensis Leaf Extract	0.1
Retinyl Palmitate	0.01
Lauryl Lactate	
1.5	
Butylene Glycol Dicaprylate/Dicaprate	5.0
Peg 100 Stearate	0.75
Polysorbate 60	2.6
Sorbitan stearate	0.9
Triethanolamine	1.0
Mica, Titanium	1.0
Glycyrrhia Glabra extract in cyclomethicone	1.0
Salix Nigra (willowbark) Extract	1.0
Oleyl alcohol, Dioscorea Villosa (Yam) Root Extract, Glycine	1.0
Sojo (soybean) sterols	
Trifolium Pratense (Clover) Flower Extract, glycerin, butylene	1.0

09497422blessing

glycol, lecithin

Water, glycerin, Macrocystis Pyrifera Extract, hydrolyzed wheat 1.0
protein
PEG-40 hydrogenated castor oil, Pyrus Malus (apple) Fruit extract 0.5
Saxifraga Sarmentosa Extract, Vitis Vinifera (grape) Fruit Extract, 0.5
butylene glycol, Morus Bombycis (Mulberry) Root extract,
Scutellaria Baicalensis Root extract, disodium EDTA, **water**
Methoxypropylgluconamide 0.3
Sodium hydroxide 0.050
Kinetin 0.05
Anthemis Nobilis Flower Extract (chamomile Roman), Salvia 0.3
Sclarea (clary) extract, citrus medica limonum (lemon) peel
extract

Water

QS

L20 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:7045 USPATFULL

TITLE: Cosmetic compositions containing extract of clover

INVENTOR(S): Reinhart, Gale McElroy, Middletown, NJ, UNITED STATES
Ferone, James Joseph, Bridgewater, NJ, UNITED STATES
Reisinger, Beverly Ann, East Brunswick, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005278	A1	20040108
APPLICATION INFO.:	US 2002-190796	A1	20020708 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Julie Blackburn, Revlon Consumer Products Corporation, 625 Madison Avenue, New York, NY, 10022		
NUMBER OF CLAIMS:	42		
EXEMPLARY CLAIM:	1		
LINE COUNT:	822		

AB A cosmetic composition comprising clover extract in combination with at least one protective agent which is a daytime protective agent, a night time protective agent, or mixtures thereof and methods for protecting skin.

DETD [0123] An oil-in-**water** emulsion cream suitable for day time wear was prepared as follows:

INGREDIENT

w/w %

Butylene glycol	5.0
Preservatives	1.73
Magnesium Ascorbyl Phosphate	0.01
Silica. . . 2.0	
Cetyl Alcohol	1.5
Stearyl Alcohol	0.75
Talc	0.75
PPG-2 Myristyl Ether Propionate	4.5
C12-15 Alkyl Benzoate	1.0
Tocopheryl Acetate	0.1
Aloe Barbadensis Leaf Extract	0.1
Retinyl Palmitate	0.01

blessing

Lauryl Lactate

1.5

Butylene Glycol Dicaprylate/Dicaprate	5.0
Peg 100 Stearate	0.75
Polysorbate 60	2.6
Sorbitan stearate	0.9
Triethanolamine	1.0
Mica, Titanium	1.0
Glycyrrhia Glabra extract in cyclomethicone	1.0
Salix Nigra (willowbark) Extract	1.0
Oleyl alcohol, Dioscorea Villosa (Yam) Root Extract, Glycine	1.0
Sojo (soybean) sterols	
Trifolium Pratense (Clover) Flower Extract, glycerin, butylene glycol, lecithin	1.0
Water , glycerin, Macrocystis Pyrifera Extract, hydrolyzed wheat protein	1.0
PEG-40 hydrogenated castor oil,	0.5
Pyrus Malus (apple) Fruit extract	
Saxifraga Sarmetosa Extract, Vitis Vinifera (grape) Fruit Extract, butylene glycol,	0.5
Morus Bombycis (Mulberry) Root extract,	
Scutellaria Baicalensis Root extract, disodium EDTA, water	
Methoxypropylgluconamide	0.3
Sodium hydroxide	0.050
Kinetin	0.05
Anthemis Nobilis Flower Extract (chamomile Roman), Salvia	0.3
Sclarea (clary) extract, citrus medica limonum (lemon) peel extract	

Water

QS

L20 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:231669 USPATFULL

TITLE: Skin-permeable selective cyclooxygenase-2 inhibitor composition

INVENTOR(S): Lu, Guang Wei, Ann Arbor, MI, UNITED STATES
 Ewing, Gary D., Kalamazoo, MI, UNITED STATES
 Tyle, Praveen, Kalamazoo, MI, UNITED STATES
 Stoller, Brenda M., Portage, MI, UNITED STATES
 Gokhale, Rajeev, Libertyville, IL, UNITED STATES
 Gadre, Ashwini, St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003161867	A1	20030828
APPLICATION INFO.:	US 2002-158342	A1	20020530 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-294838P	20010531 (60)
	US 2001-350756P	20011113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Pharmacia Corporation, Corporate Patent Department, 800 N. Lindbergh Boulevard -04B, St. Louis, MO, 63167	
NUMBER OF CLAIMS:	96	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1990	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A dermally deliverable pharmaceutical composition comprises at least one selective cyclooxygenase-2 (COX-2) inhibitory drug or prodrug thereof solubilized in a pharmaceutically acceptable carrier that comprises a low molecular weight monohydric alcohol, and exhibits a skin permeation rate of the therapeutic agent at least equal to that exhibited by a reference solution of the therapeutic agent in 70% aqueous ethanol. A method of effecting targeted delivery of a selective COX-2 inhibitory drug to a site of pain and/or inflammation in a subject comprises topically administering such a composition to skin of the subject, preferably at a locus overlying or adjacent to the site of pain and/or inflammation. A method of effecting systemic treatment of a subject having a COX-2 mediated disorder comprises transdermally administering such a composition, preferably by contacting the composition with an area of skin of the subject not greater than about 400 cm.².

DETD . . . gel formulations

Composition	15-1	15-2	15-3	15-4
parecoxib Na	2	2	2	2
hydroxypropylcellulose	3	3	3	3
HPMC 2910	3	3	3	3
polysorbate 80	1	1	1	1
oleyl alcohol	5	5	5	5
thymol	2	2	2	2
lauryl lactate	2	2.5	3	
0				
myristyl lactate	2	2.5	0	3
glyceryl dilaurate	1	0	2	2
propylene glycol	10	10	10	10
ethanol	40	40	40	40
water	29	29	29	29

L18 ANSWER 12 OF 12 USPATFULL on STN

ACCESSION NUMBER: 83:10386 USPATFULL

TITLE: Stable nonaqueous solution of tetracycline salt

INVENTOR(S): Daher, Lawrence J., Elkhart, IN, United States

Hoss, George C., Elkhart, IN, United States

Raul, Victor A., Edwardsburg, MI, United States

PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4376118		19830308
APPLICATION INFO.:	US 1981-262475		19810519 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1980-194556, filed on 6 Oct 1980, now Defensive Publication No.		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Nicky		
ASSISTANT EXAMINER:	Moezie, F. T.		
LEGAL REPRESENTATIVE:	Davidson, Louis E.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	639		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nonaqueous solution of a tetracycline antibiotic salt which is stable upon extended storage comprises a mixture of a tetracycline antibiotic salt, nonaqueous diluent, nonaqueous solvent, and nonaqueous nonionic solubilizer. It preferably also contains an antioxidant and a nonaqueous anionic solubilizer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CLM What is claimed is:

- . . . a nonaqueous diluent material selected from the class consisting of glyceryl triacetate, diisopropyl sebacate, diisopropyl adipate, ~~isopropyl~~ palmitate, isopropyl myristate, **lauryl lactate**, linear alcohol lactate, decyl oleate, isodecyl oleate, 2-ethylhexyl palmitate, isopropyl linoleate, acetylated monoglyceride, acetyl tributyl citrate, acetyl triethyl citrate, tricyclo. . . and acetone, 0.3 to 20 percent nonaqueous nonionic solubilizer selected from the class consisting of polyethylene glycols, methoxy polyethylene glycols, **polysorbates**, ethylene oxide-propylene oxide block copolymers, sorbitan esters and glycerin, 0 to 6 percent nonaqueous anionic solubilizer selected from the class. . .

L18 ANSWER 9 OF 12 USPATFULL on STN

ACCESSION NUMBER: 1998:19293 USPATFULL
TITLE: Titanium-tin-oxide nanoparticles, compositions
utilizing the same, and the method of forming the same
INVENTOR(S): Wellenghoff, Stephen T., San Antonio, TX, United States
Cernasov, Domnica, Ringwood, NJ, United States
PATENT ASSIGNEE(S): Southwest Research Institute, San Antonio, TX, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5720805		19980224
APPLICATION INFO.:	US 1996-714933		19960927 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-298836, filed on 31 Aug 1994, now patented, Pat. No. US 5670583 which is a division of Ser. No. US 1993-47750, filed on 13 Apr 1993, now patented, Pat. No. US 5372796		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Marcheschi, Michael		
LEGAL REPRESENTATIVE:	Sigalos, John L.		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	432		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed stabilized Ti-Sn-O nanoclusters formed by complexing Ti-Sn-O nanoclusters with a salt of an alpha-hydroxy acid and also complexed nanoclusters with increased charge transfer interaction formed by annealing the complexed nanoclusters. Also disclosed are compositions for protection against ultraviolet radiation in which the nanoclusters are utilized with the usual topical carriers in an amount to give the level of sun protection factor (SPF) desired. Further disclosed is the method of making the nanoclusters involving acid hydrolyzing a titanium alkoxide and then reacting the hydrolyzed alkoxide with a tin halide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD Cetoaryl alcohol, cetyl alcohol, DEA-cetyl phosphate, disodium laureth sulfosuccinate, glycol distearate, Laneth-40, **lauryl lactate**, magnesium lauryl sulphate, Oleth-3, PEG-2 diisononanoate, PEG-150, PEG-15 cocamine, PEG-40 hydrogenated castor oil, PEG-8 laurate, PEG-20 stearate, **Polysorbate 20**, PPG-4 myristyl ether acetate, sorbitan laurate, sorbitan stearate, Stearate-10, and the like.

L18 ANSWER 10 OF 12 USPATFULL on STN

ACCESSION NUMBER: 97:83995 USPATFULL
TITLE: Composition and method enhancing transdermal
electrotransport agent delivery
INVENTOR(S): Gyory, J. Richard, San Jose, CA, United States
PATENT ASSIGNEE(S): ALZA Corporation, Palo Alto, CA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5668170		19970916

09497422blessing

APPLICATION INFO.: US 1996-612378 19960307 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-274619, filed on 13
Jul 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Seidleck, James J.
ASSISTANT EXAMINER: Truong, Dunc
LEGAL REPRESENTATIVE: Miller, D. Byron, Cagan, Felissa H., Stone, Steven F.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 990

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprises an agent to be delivered through a body surface and an electrotransport enhancer having a hydrophobic tail and a polar head of specific characteristics. An electrotransport delivery device is also provided having a reservoir comprising the agent to be delivered and the electrotransport enhancer of the invention. The electrotransport enhancers increase the electrotransport delivery rate of the agent through the surface while reducing the electrical resistance of the surface during electrotransport of the agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD					8.6	191	3	1.01	.98
monolaurate									
PEG-4	9.5	221	2	1.05				.74	
monolaurate									
Laurampho-									
	54	260	2	0.99				.93	
carboxy-									
propionate									
BRIJ 35	17	1029	2	1.04				.94	
Polysorbate-20									
	17	2783	2	0.92				.96	
Lauryl lactate									
	4.7	89	3	0.97				.92	
PEG-4	6	248	2	0.97				.76	
Dilaurate									

*HLB denotes hydrophilelipophile balance.

**n denotes number of samples tested.

DETD . . . mass flux and decreased skin resistance. Enhancers with weakly polar groups, such as PEG-4 monolaurate, PEG-4 dilaurate, Brij 35, and **lauryl lactate**, reduced skin resistivity, none of these enhanced the mass flux of metaclopramide. Sorbitan monolaurate, and **polysorbate-20** have hydrophilic sugar moieties but fail to have a significant effect on either the electrotransport flux of metaclopramide or the. . .

L18 ANSWER 11 OF 12 USPATFULL on STN

ACCESSION NUMBER: 96:118367 USPATFULL

TITLE: Topical application emulsions

INVENTOR(S): Punto, Louis, Clearwater, FL, United States

Potini, Chim, Largo, FL, United States

Duque, Pilar, Tampa, FL, United States

Gould, Eva, Tampa, FL, United States

PATENT ASSIGNEE(S): R.P. Scherer Corporation, Troy, MI, United States (U.S.)

blessing

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5587149		19961224
APPLICATION INFO.:	US 1995-383782		19950206 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fan, Jane		
ASSISTANT EXAMINER:	Huang, Evelyn		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	398		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates in general to products for topical application to the skin, and more particularly to improved stable emulsions for containing water soluble active ingredients, such as Vitamin C, glycolic acid, etc., which may nonetheless be packaged with gelatin capsules, and which have demonstrated improved stability.

In particular, the invention relates to a novel polyethylene glycol-in-oil emulsion that is compatible with gelatin capsules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . Name

PEG-400, PEG-600,

Union Carbide

Polyethylene Glycol

PEG-1000

Silicone Fluids

Dow-Corning Cyclomethicone

244, 245, 344, 345

Silicone Fluid

Dow-Corning Cyclomethicone and
Dimethicone Copolyol

3225C

Tween-20 ICI Americas **Polysorbate-20**

Protochem GL-7,

Protameen Ethoxylated-7

GL-26

Chemical Glycerin and
Ethoxylated-26
Glycerin

ABIL WE-09

Goldschmidt Polyglyceryl-4
Isostearate and cetyl
Dimethicone Copolyol
and Hexyl Laurate

Down-Corning

Dow-Corning Dimethicone

Fluid 200

Dow-Corning Dow-Corning Cyclomethicone and

Fluid 1401 Dimethiconol

Dow-Corning Dow-Corning Dimethicone and

Fluid 1403 Dimethiconol

Ceraphyl 31 ISP-Vandyk **Lauryl Lactate**

Scheremol DIA

09497422blessing

Scher and Co.

Diisopropyl Adipate

MFA-Complex Barnett and Co.

Alpha hydroxy Acid
Complex

Dry-Flow PC National Starch

Aluminum Starch
Octylsuccinate

Syncrowax HR-C

blessing

L18 ANSWER 1 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2004:38188 USPATFULL
 TITLE: Pharmaceutical preparation of percutaneous absorption type
 INVENTOR(S): Terahara, Takaaki, Tsukuba-shi, JAPAN
 Aida, Kazunosuke, Tsukuba-shi, JAPAN
 Higo, Naruhito, Tsukuba-shi, JAPAN
 Sato, Shuji, Tsukuba-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004028724	A1	20040212
APPLICATION INFO.:	US 2003-416628	A1	20030506 (10)
	WO 2001-JP9496		20011030

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-339524	20001107
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 9169, BOSTON, MA, 02209	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	716	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An adhesive pharmaceutical preparation of the percutaneous absorption type containing an acid addition salt of a basic drug or amphoteric drug, in which the medicinal component highly permeates the skin and which is reduced in skin irritation and excellent in physical stability. The preparation comprises an aminated polymer, a drug in the form of an acid addition salt, and a carboxylic acid or/and a salt thereof, and is characterized in that the content of the aminated polymer is up to 50 weight % based on the whole preparation, the amount of the amino groups contained in the polymer is 0.5 mol or higher per mol of the drug, and the amount of the carboxylic acid or/and salt thereof is 1 to 10 mol per mol of the sum of the drug and the amino groups contained in the polymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . isopropyl myristate, myristyl myristate, octyl dodecyl myristate, cetyl palmitate, salicylic acid, methyl salicylate, ethyleneglycol salicylate, methyl cinnamate, cresol, cetyl lactate, **lauryl lactate**, ethyl acetate, propyl acetate, geraniol, thymol, eugenol, terpinerol, 1-menthol, bornerol, d-limonene, isoeugenol, isobornierol, nerol, dl-camphor, glycerine monocaprylate, glycerine monocaprinate, glycerine monolaurate, glycerine monooleate, sorbitan monolaurate, sucrose monolaurate, **polysorbate 20**, propyleneglycol, propyleneglycol monolaurate, polyethyleneglycol monolaurate, polyethyleneglycol monostearate, polyoxyethylene lauryl ether, HCO-60, pirotiodecane, olive oil and the like. In particular, . . .

L18 ANSWER 2 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2004:12612 USPATFULL
 TITLE: Compositions for treating keratinous surfaces
 INVENTOR(S): Detore, Donna Marie, Morris Plains, NJ, UNITED STATES

Reinhart, Gale McElroy, Middletown, NJ, UNITED STATES
 Ferone, James Joseph, Bridgewater, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009130	A1	20040115
APPLICATION INFO.:	US 2002-190804	A1	20020708 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Revlon Consumer Products Corporation, 625 Madison Avenue, New York, NY, 10022		
NUMBER OF CLAIMS:	42		
EXEMPLARY CLAIM:	1		
LINE COUNT:	928		
AB	A cosmetic composition comprising a mixture of extracts from yam and soy in combination with at least one protective agent which is a daytime protective agent, a night time protective agent, or mixtures thereof and methods for ameliorating the adverse effects of aging and menopause on skin.		

DETD . . . 2.0	
Cetyl Alcohol	1.5
Stearyl Alcohol	0.75
Talc	0.75
PPG-2 Myristyl Ether Propionate	4.5
C12-15 Alkyl Benzoate	1.0
Tocopheryl Acetate	0.1
Aloe Barbadosensis Leaf Extract	0.1
Retinyl Palmitate	0.01
Lauryl Lactate	
1.5	
Butylene Glycol Dicaprylate/Dicaprate	5.0
Peg 100 Stearate	0.75
Polysorbate 60	2.6
Sorbitan stearate	0.9
Triethanolamine	1.0
Mica, Titanium	1.0
Glycyrrhia Glabra extract in cyclomethicone	1.0
Salix Nigra (willowbark) Extract	1.0
Oleyl alcohol, Dioscorea Villosa (Yam). . .	

L18 ANSWER 3 OF 12 USPATFULL on STN
 ACCESSION NUMBER: 2004:7045 USPATFULL
 TITLE: Cosmetic compositions containing extract of clover
 INVENTOR(S): Reinhart, Gale McElroy, Middletown, NJ, UNITED STATES
 Ferone, James Joseph, Bridgewater, NJ, UNITED STATES
 Reisinger, Beverly Ann, East Brunswick, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005278	A1	20040108
APPLICATION INFO.:	US 2002-190796	A1	20020708 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Julie Blackburn, Revlon Consumer Products Corporation, 625 Madison Avenue, New York, NY, 10022		

09497422blessing

NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 822

AB A cosmetic composition comprising clover extract in combination with at least one protective agent which is a daytime protective agent, a night time protective agent, or mixtures thereof and methods for protecting skin.

DETD 2.0	
Cetyl Alcohol	1.5
Stearyl Alcohol	0.75
Talc	0.75
PPG-2 Myristyl Ether Propionate	4.5
C12-15 Alkyl Benzoate	1.0
Tocopheryl Acetate	0.1
Aloe Barbadensis Leaf Extract	0.1
Retinyl Palmitate	0.01
Lauryl Lactate	
1.5	
Butylene Glycol Dicaprylate/Dicaprate	5.0
Peg 100 Stearate	0.75
Polysorbate 60	2.6
Sorbitan stearate	0.9
Triethanolamine	1.0
Mica, Titanium	1.0
Glycyrrhia Glabra extract in cyclomethicone	1.0
Salix Nigra (willowbark) Extract	1.0
Oleyl alcohol, Dioscorea Villosa (Yam). . .	

L18 ANSWER 4 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2003:231669 USPATFULL

TITLE: Skin-permeable selective cyclooxygenase-2 inhibitor composition

INVENTOR(S): Lu, Guang Wei, Ann Arbor, MI, UNITED STATES
Ewing, Gary D., Kalamazoo, MI, UNITED STATES
Tyle, Praveen, Kalamazoo, MI, UNITED STATES
Stoller, Brenda M., Portage, MI, UNITED STATES
Gokhale, Rajeev, Libertyville, IL, UNITED STATES
Gadre, Ashwini, St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003161867	A1	20030828
APPLICATION INFO.:	US 2002-158342	A1	20020530 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-294838P	20010531 (60)
	US 2001-350756P	20011113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Pharmacia Corporation, Corporate Patent Department, 800 N. Lindbergh Boulevard -04B, St. Louis, MO, 63167	
NUMBER OF CLAIMS:	96	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1990	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blessing

AB A dermally deliverable pharmaceutical composition comprises at least one selective cyclooxygenase-2 (COX-2) inhibitory drug or prodrug thereof solubilized in a pharmaceutically acceptable carrier that comprises a low molecular weight monohydric alcohol, and exhibits a skin permeation rate of the therapeutic agent at least equal to that exhibited by a reference solution of the therapeutic agent in 70% aqueous ethanol. A method of effecting targeted delivery of a selective COX-2 inhibitory drug to a site of pain and/or inflammation in a subject comprises topically administering such a composition to skin of the subject, preferably at a locus overlying or adjacent to the site of pain and/or inflammation. A method of effecting systemic treatment of a subject having a COX-2 mediated disorder comprises transdermally administering such a composition, preferably by contacting the composition with an area of skin of the subject not greater than about 400 cm.^{sup.2}.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . gel formulations

Composition	15-1	15-2	15-3	15-4
parecoxib Na	2	2	2	2
hydroxypropylcellulose	3	3	3	3
HPMC 2910	3	3	3	3
polysorbate 80	1	1	1	1
oleyl alcohol	5	5	5	5
thymol	2	2	2	2
lauryl lactate	2	2.5	3	
0				
myristyl lactate	2	2.5	0	3
glyceryl dilaurate	1	0	2	2
propylene glycol	10	10	10	10
ethanol	40.	.	.	.

L18 ANSWER 5 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2003:158996 USPATFULL

TITLE: Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

INVENTOR(S): Berry, Stephen A., Hollister, CA, UNITED STATES
 Ferreira, Pamela J., Redwood City, CA, UNITED STATES
 Dehnad, Houdin, El Granada, CA, UNITED STATES
 Muchnik, Anna, Belmont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003108609	A1	20030612
APPLICATION INFO.:	US 2002-319277	A1	20021212 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-497422, filed on 3 Feb 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-119170P	19990208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALZA CORPORATION, P O BOX 7210, INTELLECTUAL PROPERTY DEPARTMENT, MOUNTAIN VIEW, CA, 940397210	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	

09497422blessing

NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 948

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1+10.sup.-7 reciprocal second.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD	. . .	50:15:35	7,000	
PVP	--	LA	60:40	
PVP	Ceraphyl 50	LA	60:10:30	
PVP	--	oleic acid	50:50	30,000
PVP	--	octanoic acid	55:45	7.000
PVP	polysorbate 80	--	50:50	
PVP	--	PEG 400	50:50	
PVP	caster oil	--	50:50	
--	Pluronic 105	--	100	1,000,000
PVP	--	glycerin	50:50	5,000

Wherein:

GML = glycerol monolaurate

LL = **lauryl lactate**

PVP = polyvinylpyrrolidone C30

LA = lauryl alcohol

PEG = polyethyleneglycol 400

CLM What is claimed is:

11. The vehicle of claim 4 wherein the polymer is polyvinylpyrrolidone, the surfactant is **polysorbate**, and the solvent is **lauryl lactate**.

L18 ANSWER 6 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2002:206688 USPATFULL

TITLE: PHARMACEUTICAL DOSAGE FORM FOR TRANSDERMAL ADMINISTRATION

INVENTOR(S): LAURENT, PHILIPPE, OULLINS, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002111387	A1	20020815
	US 6538039	B2	20030325
APPLICATION INFO.:	US 1996-741967	A1	19961031 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-428958, filed on 26 Apr 1995, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-5272	19940429
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JACOBSON PRICE HOLMAN AND STERN, 400 SEVENTH STREET NW, WASHINGTON, DC, 20004	

blessing

NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a process for administering an active principle to a patient transdermally, which comprises the formation of a film on the patient's skin, by applying to the skin a liquid solution which consists essentially of:

- a) a lipophilic active principle,
- b) from 2.5 to 25 % by weight of a silicone-based adhesive polymer composition,
- c) from 0 to 25% by weight of an absorption promoter, and
- d) from 25 to 95% by weight of volatile solvents comprising volatile silicones.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . glycerides (with 8 to 10 ethylene oxide units), Azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, isopropylmyristate, octylmyristate, dodecyl-myristate, myristyl alcohol, lauryl alcohol, lauric acid, **lauryl lactate**, terpinol, 1-menthol, d-limonene, β -cyclodextrin and its derivatives or surfactants such as **polysorbates**, sorbitan esters, sucrose esters, fatty acids, bile salts, or alternatively lipophilic and/or hydrophilic and/or amphiphilic products such as poly-glycerol esters,.

L18 ANSWER 7 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2002:106351 USPATFULL
TITLE: Gel compositions
INVENTOR(S): Butuc, S. Gina, Woodlands, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055562	A1	20020509
APPLICATION INFO.:	US 2001-853552	A1	20010511 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-419571, filed on 18 Oct 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106094P	19981029 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JENKENS & GILCHRIST, PC, 1445 ROSS AVENUE, SUITE 3200, DALLAS, TX, 75202	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	2200	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Two-phase gel compositions are provided. The two-phase gel compositions are obtained by mixing a gelled ester composition comprising a mixture of an ester compound and a polymer compound selected from the group

consisting of triblock copolymers, star polymers, radial polymers, multi-block copolymers, and a combination thereof and a hydrophobic, non polar solvent. The gelled ester composition has a viscosity $\eta_{\text{sub.1}}$ and the solvent has a viscosity $\eta_{\text{sub.2}}$. The two-phase gel composition is substantially free of phosphate compounds and has a viscosity η which is greater than or equal to $\eta_{\text{sub.1}}$ and which is greater than or equal to $\eta_{\text{sub.2}}$. The two-phase gel compositions are also obtained by mixing a gelled ether composition, a gelled alcohol composition, a gelled naturally-occurring fat and oil composition or a combination thereof with a hydrophobic, non polar solvent. The two-phase gel compositions may be used to suspend various solids, liquids and/or gases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . Laureth-6 Citrate; Laureth-7 Citrate; Laureth-2 Octanoate; Laureth-7 Tartrate; Lauroyl Ethyl Glucoside; Lauroyl Lactic Acid; Lauryl Behenate; Lauryl Cocoate; Lauryl Isostearate; **Lauryl Lactate**; Lauryl Methacrylate; Lauryl Myristate; Lauryl Octanoate; Lauryl Oleate; Lauryl Palmitate; Lauryl Stearate; Linalyl Acetate; Linoleyl Lactate; Madecassicose; Mannitan Laurate; Mannitan. . . Phenylparaben; Phenyl Salicylate; Phyllosteryl Macadamiate; Poloxamer 105 Benzoate; Poloxamer 182 Dibenzoate; Polycaprolactone; Polydimethylaminoethyl Methacrylate; Polyethylacrylate; Polyethylglutamate; Polyethylmethacrylate; Polymethyl Acrylate; Polymethylglutamate; **Polysorbate** 80 Acetate; Polyvinyl Acetate; Potassium Butylparaben; Potassium Deceth-4 Phosphate; Potassium Ethylparaben; Potassium Methylparaben; Potassium Propylparaben; PPG-2 Isoceleth-20 Acetate; PPG- 14. . .

L18 ANSWER 8 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2001:220682 USPATFULL
 TITLE: Film forming composition for spraying on the skin
 INVENTOR(S): Laurent, Philippe, Oulins, France
 PATENT ASSIGNEE(S): Lafon, Laboratoire L., Maisons Alfort, France (non-U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6325990	B1	20011204
	WO 9715295		19970501
APPLICATION INFO.:	US 1998-51719		19980507 (9)
	WO 1996-FR1628		19961017
			19980507 PCT 371 date
			19980507 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1995-12393	19951020
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Bawa, Raj	
LEGAL REPRESENTATIVE:	Jacobson Holman, PLLC	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	300	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition is intended to form on the skin, by spraying from an

erasol can, a film for the transdermal administration of an active agent, and the composition contains 0.01-10% by weight of lipophilic vitamins, hormones, nicotine, corticoids, retinoids, antimycotic agents, anisthetics, anolgesics, or anti cancer agents for the skin, 0.5 to 25% by weight of an adhesive polysiloxane composition, 5 to 25% by weight of an absorption promoter, 25 to 95% by weight of a volatile solvent containing at least a volatile silicone, and 0.5 to 50% by weight of pressurized propellant gas, and the composition is substantially free from water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane, isopropyl myristate, octyl myristate, dodecyl myristate, myristyl alcohol, lauryl alcohol, lauric acid, **lauryl lactate**, terpeneol, 1-menthol, D-limonene, β -cyclodextrin and its derivatives or surfactants such as **polysorbates**, sorbitan esters, sucrose esters, fatty acids and bile salts, or alternatively lipophilic and/or hydrophilic and/or amphiphilic products such as polyglycerol. . .

L18 ANSWER 9 OF 12 USPATFULL on STN

ACCESSION NUMBER: 1998:19293 USPATFULL
 TITLE: Titanium-tin-oxide nanoparticles, compositions utilizing the same, and the method of forming the same
 INVENTOR(S): Wellingshoff, Stephen T., San Antonio, TX, United States
 Cernasov, Domnica, Ringwood, NJ, United States
 PATENT ASSIGNEE(S): Southwest Research Institute, San Antonio, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5720805		19980224
APPLICATION INFO.:	US 1996-714933		19960927 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-298836, filed on 31 Aug 1994, now patented, Pat. No. US 5670583 which is a division of Ser. No. US 1993-47750, filed on 13 Apr 1993, now patented, Pat. No. US 5372796		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Marcheschi, Michael		
LEGAL REPRESENTATIVE:	Sigalos, John L.		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	432		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed stabilized Ti-Sn-O nanoclusters formed by complexing Ti-Sn-O nanoclusters with a salt of an alpha-hydroxy acid and also complexed nanoclusters with increased charge transfer interaction formed by annealing the complexed nanoclusters. Also disclosed are compositions for protection against ultraviolet radiation in which the nanoclusters are utilized with the usual topical carriers in an amount to give the level of sun protection factor (SPF) desired. Further disclosed is the method of making the nanoclusters involving acid hydrolyzing a titanium alkoxide and then reacting the hydrolyzed alkoxide with a tin halide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

09497422blessing

DETD Cetoaryl alcohol, cetyl alcohol, DEA-cetyl phosphate, disodium laureth sulfosuccinate, glycol distearate, Laneth-40, **lauryl lactate**, magnesium lauryl sulphate, Oleth-3, PEG-2 diisononanoate, PEG-150, PEG-15 cocamine, PEG-40 hydrogenated castor oil, PEG-8 laurate, PEG-20 stearate, **Polysorbate 20**, PPG-4 myristyl ether acetate, sorbitan laurate, sorbitan stearate, Stearate-10, and the like.

L18 ANSWER 10 OF 12 USPATFULL on STN

ACCESSION NUMBER: 97:83995 USPATFULL

TITLE: Composition and method enhancing transdermal electrotransport agent delivery

INVENTOR(S): Gyory, J. Richard, San Jose, CA, United States

PATENT ASSIGNEE(S): ALZA Corporation, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5668170		19970916
APPLICATION INFO.:	US 1996-612378		19960307 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-274619, filed on 13 Jul 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Seidleck, James J.		
ASSISTANT EXAMINER:	Truong, Dunc		
LEGAL REPRESENTATIVE:	Miller, D. Byron, Cagan, Felissa H., Stone, Steven F.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	990		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprises an agent to be delivered through a body surface and an electrotransport enhancer having a hydrophobic tail and a polar head of specific characteristics. An electrotransport delivery device is also provided having a reservoir comprising the agent to be delivered and the electrotransport enhancer of the invention. The electrotransport enhancers increase the electrotransport delivery rate of the agent through the surface while reducing the electrical resistance of the surface during electrotransport of the agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD				8.6	191	3	1.01	.98
monolaurate								
PEG-4	9.5	221	2	1.05			.74	
monolaurate								
Laurampho-								
	54	260	2	0.99			.93	
carboxy-								
propionate								
BRIJ 35	17	1029	2	1.04			.94	
Polysorbate-20								
	17	2783	2	0.92			.96	
Lauryl lactate								
	4.7	89	3	0.97			.92	
PEG-4	6	248	2	0.97			.76	
Dilaurate								

blessing

*HLB denotes hydrophilelipophile balance.

**n denotes number of samples tested.

DETD . . . mass flux and decreased skin resistance. Enhancers with weakly polar groups, such as PEG-4 monolaurate, PEG-4 dilaurate, Brij 35, and **lauryl lactate**, reduced skin resistivity, none of these enhanced the mass flux of metaclopramide. Sorbitan monolaurate, and **polysorbate-20** have hydrophilic sugar moieties but fail to have a significant effect on either the electrotransport flux of metaclopramide or the. . .

L18 ANSWER 11 OF 12 USPATFULL on STN

ACCESSION NUMBER: 96:118367 USPATFULL

TITLE: Topical application emulsions

INVENTOR(S): Punto, Louis, Clearwater, FL, United States

Potini, Chim, Largo, FL, United States

Duque, Pilar, Tampa, FL, United States

Gould, Eva, Tampa, FL, United States

PATENT ASSIGNEE(S): R.P. Scherer Corporation, Troy, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 5587149		19961224
APPLICATION INFO.:	US 1995-383782		19950206 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fan, Jane		
ASSISTANT EXAMINER:	Huang, Evelyn		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	398		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates in general to products for topical application to the skin, and more particularly to improved stable emulsions for containing water soluble active ingredients, such as Vitamin C, glycolic acid, etc., which may nonetheless be packaged with gelatin capsules, and which have demonstrated improved stability.

In particular, the invention relates to a novel polyethylene glycol-in-oil emulsion that is compatible with gelatin capsules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . Name

PEG-400, PEG-600,

Union Carbide

Polyethylene Glycol

PEG-1000

Silicone Fluids

Dow-Corning Cyclomethicone

244, 245, 344, 345

Silicone Fluid

Dow-Corning Cyclomethicone and

3225C Dimethicone Copolyol

09497422blessing

Tween-20 ICI Americas Polysorbate-20
Protochem GL-7,
GL-26 Protameen Ethoxylated-7
Chemical Glycerin and
Ethoxylated-26
Glycerin
ABIL WE-09 Goldschmidt Polyglyceryl-4
Isostearate and cetyl
Dimethicone Copolyol
and Hexyl Laurate
Down-Corning
Dow-Corning Dimethicone
Fluid 200
Dow-Corning Dow-Corning Cyclomethicone and
Fluid 1401 Dimethiconol
Dow-Corning Dow-Corning Dimethicone and
Fluid 1403 Dimethiconol
Ceraphyl 31 ISP-Vandyk Lauryl Lactate
Scheremol DIA
Scher and Co.
Diisopropyl Adipate
MFA-Complex Barnett and Co.
Alpha hydroxy Acid
Complex
Dry-Flow PC National Starch
Aluminum Starch
Octylsuccinate

Syncrowax HR-C

L18 ANSWER 12 OF 12 USPATFULL on STN
ACCESSION NUMBER: 83:10386 USPATFULL
TITLE: Stable nonaqueous solution of tetracycline salt
INVENTOR(S): Daher, Lawrence J., Elkhart, IN, United States
Hoss, George C., Elkhart, IN, United States
Raul, Victor A., Edwardsburg, MI, United States
PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4376118		19830308
APPLICATION INFO.:	US 1981-262475		19810519 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1980-194556, filed on 6 Oct 1980, now Defensive Publication No.		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Nicky		
ASSISTANT EXAMINER:	Moezie, F. T.		
LEGAL REPRESENTATIVE:	Davidson, Louis E.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	639		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Nonaqueous solution of a tetracycline antibiotic salt which is stable upon extended storage comprises a mixture of a tetracycline antibiotic salt, nonaqueous diluent, nonaqueous solvent, and nonaqueous nonionic		

blessing

solubilizer. It preferably also contains an antioxidant and a nonaqueous anionic solubilizer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CLM What is claimed is:

- . . . a nonaqueous diluent material selected from the class consisting of glyceryl triacetate, diisopropyl sebacate, diisopropyl adipate, isopropyl palmitate, isopropyl myristate, **lauryl lactate**, linear alcohol lactate, decyl oleate, isodecyl oleate, 2-ethylhexyl palmitate, isopropyl linoleate, acetylated monoglyceride, acetyl tributyl citrate, acetyl triethyl citrate, tricyclo. . . and acetone, 0.3 to 20 percent nonaqueous nonionic solubilizer selected from the class consisting of polyethylene glycols, methoxy polyethylene glycols, **polysorbates**, ethylene oxide-propylene oxide block copolymers, sorbitan esters and glycerin, 0 to 6 percent nonaqueous anionic solubilizer selected from the class. . .